The clinical utility of neutrophil to lymphocyte ratio in pregnancy related complications: a mini-review
Review Article

The clinical utility of neutrophil to lymphocyte ratio in pregnancy related complications: a mini-review

Ling Hai1,2, Zhi-De Hu3

1Department of Pathology, School of Basic Medical Science, Inner Mongolia Medical University, Hohhot 010110, China; 2Department of Pathology, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China; 3Department of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China

Contributions: (I) Conception and design: ZD Hu; (II) Administrative support: L Hai; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Zhi-De Hu. Department of Laboratory Medicine, the Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China. Email: hzdlj81@163.com.

Abstract: Pregnancy-related complications (PRCs) are potent contributors to mortality and morbidity in pregnant women. Prediction and early recognition of PRCs are crucial to improve its prognosis. The pathogenesis of PRCs is complex and it is well-recognized that inflammation response is involved in several types of PRCs. Therefore, inflammatory markers are usually used as predictors or prognostic factors in PRCs. Neutrophil to lymphocyte ratio (NLR), which is calculated from complete blood count and dedifferentiation, is a simple and easily obtainable inflammatory index. Accumulated studies have shown that NLR is an indicator of PRCs. In this minireview, we summarized the evidence regarding the clinical utility of NLR in PRCs, including preeclampsia, gestational diabetes mellitus, hyperemesis gravidarum, preterm delivery and ectopic pregnancy.

Keywords: Neutrophil to lymphocyte ratio (NLR); pregnancy-related complications (PRCs); inflammation


Received: 25 September 2019; Accepted: 12 October 2019; Published: 20 January 2020.

doi: 10.21037/jlpm.2019.10.03


Introduction

Neutrophil to lymphocyte ratio (NLR), which can be easily calculated from complete blood count and leukocyte differential count, is an inexpensive parameter with multiple clinical applications. For example, accumulated evidences have indicated that NLR is a prognostic factor for heart failure (1), adult subarachnoid hemorrhage (2) and gastric cancer (3). One of the possible mechanisms underlying the multiple applications of NLR is inflammation response, which increases circulating neutrophils and decreased lymphocytes (4,5).

Pregnancy related complications (PRCs), such as preeclampsia (PE) and gestational diabetes mellitus (GDM), are potent contributors to mortality and morbidity in pregnant women. Early diagnosis and prediction of PRCs are crucial to improve its outcomes. Interestingly, inflammation response is involved in the pathogenesis of nearly all types of these complications (6-8). Therefore, inflammation indicators, such as C-reactive protein (CRP) and interleukin 6 (IL-6), are associated with the occurrence of PRCs (9-11).

Because NLR is a simple and inexpensive inflammatory indicator, accumulated studies have investigated the clinical utility of NLR during pregnancy. Therefore, we summarized and commented the currently available evidence regarding NLR and PRCs. In this review, we categorized the available studies into the cross-sectional, case-control and cohort studies. This information was not extracted from the original reports, but justified by the author. Cross-sectional design was defined as any studies that measure exposure factors and outcomes simultaneously. Case-control design was defined as any studies in which outcomes are firstly obtained and exposure factors before the occurrence of outcomes are retrospectively obtained. Cohort design was defined as any studies in which exposure factors are firstly obtained and subjects are followed until the occurrence of outcome.


PE

PE is a major cause of mortality and morbidity for both mother and fetus around the world (12). It is characterized by hypertension and proteinuria after 20 weeks of pregnancy (12). The prevalence of PE is around 1% to 8% (13-15). Although the pathogenesis of PE is largely unknown, animal and clinical studies indicate that inflammation response is critically involved in the occurrence and development of PE (6,16,17). Because NLR is simple indicator of inflammation response, some studies have investigated the clinical utility of NLR in PE.

Two cross-sectional studies published in 2014 (18,19) investigated the relationship between NLR and PE, but the results are inconsistent. One study found that NLR in PE patients was higher than that in normal pregnant woman, and increased NLR was independently associated with PE after adjusting for cofounding factors (19). The other study determined the NLR level before the caesarean delivery but failed to find the increased NLR in PE (18). Subsequently, several cross-sectional studies have investigated the relationship between PE and NLR, and the results varied (20-28). Some studies found that NLR was higher in PE than in normal pregnant women (20-25,28), while one study failed to demonstrate a significant difference (27). In addition, some of the studies indicated that NLR was associated with severity (22-24), outcome (21), and proteinuria (24) of PE.

Currently, four case-control studies investigated the relationship between NLR and PE (20,29-31). Two of these four studies indicated that increased NLR in first (30) and second trimester (31) was a risk factor for PE. But in one study with large sample size (118 PE patients and 1,495 normal pregnant women), the authors failed to found NLR before the twentieth pregnancy week was increased in PE patients (20).

Taken together, the current evidence regarding NLR and PE is not consistent, and majority of the current evidence is cross-sectional or case-control design. Therefore, prospective cohort studies and meta-analyses are needed to provide robust evidence regarding the clinical utility of NLR in PE.


Hemolysis, elevated liver enzymes, low-platelet count (HELLP) syndrome

HELPP syndrome is characterized by hemolysis, liver injury, and decreased platelet count in the third trimester of pregnancy (32,33). To present, two studies from the one group have investigated the clinical utility of NLR in HELLP syndrome (34,35). In a case-control study, the author enrolled 14 HELLP syndrome patients and 14 age-matched normal pregnant women and found that NLR in third trimester was significantly increased in HELPP syndrome patients (35). Contrarily in a cross-sectional study the authors failed to prove that NLR in the third trimester was increased in PE (34). Considering that the sample sizes in these two studies are small and cofounding factors were not fully considered, further studies are needed to investigate the utility of NLR in HELLP syndrome management.


GDM

GDM is defined as glucose metabolism disorder that occurs for the first time during pregnancy, and inflammation is believed to be involved in the pathogenesis of GDM (36). In 2014, a cross-sectional study with 42 GDM and 68 non-GDM indicated that NLR was increased in GDM patients, and NLR was independently associated with GDM in a multivariable logistic regression model (37). However, a subsequent study with large sample size failed to found the increased NLR in GMD (38). The possible reasons for the inconsistency are largely unknown. In a recently published work, the researcher included 114 GDM and 114 well-matched non-GDM and found that NLR was increased in GDM patients (39). Furthermore, NLR was independently associated with HbA1c in a multivariable liner regression model (39). Taken together, current evidence regarding GDM and NLR is controversial, and further studies, especially prospective cohort studies, are needed to illustrate the clinical utility of NLR in GDM.


Ectopic pregnancy (EP)

EP is a complication of pregnancy which is defined as the implantation of the embryo outside the uterine cavity (40). Currently, methotrexate (MTX) and surgery are usually used for EP treatment in clinical practice. MTX is a noninvasive treatment approach and thus much preferred by obstetricians. However, the benefit and hazard of MTX should be balanced when deciding the treatment approach. Generally, MTX is usually used in patients with stable hemodynamics, smaller pregnancy mass size, lower beta-subunit human chorionic gonadotropin (β-hCG), while surgery is used in the remaining. However, the board line between MTX and surgery is not always clear in clinical practice. For some patients, treatment approach selection is really a challenge for obstetricians.

In a study published in 2017, the researchers compared the clinical and laboratory characteristic of EP patients received MTX (n=93) and surgery (n=60) (41). They found that NLR was significantly increased in patients received surgery, indicating that NLR was helpful in the choice of the EP treatment. This finding was validated by a subsequent study (42). In a study published recently, the researcher found that EP patients with tubal rupture had higher NLR than these without (43), also supports that NLR can assist obstetricians choosing treatment approach. Further, in one study with 78 MTX treatment successful and 37 MTX treatment failure patients, higher NLR was observed in MTX treatment successful patients (44), indicating that NLR is a predictor of MTX treatment efficiency.


Hyperemesis gravidarum (HG)

HG is a serious complication characterized by nausea and vomiting in first trimester of pregnancy. It can lead to dehydration, ketonuria, fluid and electrolyte imbalance, and weight loss (45). Some studies have compared the NLR level between normal pregnant women and HG patients (46-51) and all of them found that NLR was increased in HG patients. One study found that NLR increased as the advance of HG severity (47), indicating that NLR is a useful indicator in estimating the severity of HG. However, this finding was not validated in other two studies (48,51). Notably, all of these studies are cross-sectional and the therefore causality cannot be established. Further prospective cohort studies are needed to verify whether NLR is a risk factor for HG.


Preterm delivery (PD)

PD, defined as birth before 37 weeks’ gestation, is the major cause of perinatal morbidity and mortality worldwide. Some pregnant women may present with threatened preterm labor (TPL) on admission, but delivery does not occur after a tocolytics treatment. It is of great value to identify TPL women who will give birth preterm. Some studies have investigated the value of NLR in predicting PD (52-57). In three retrospective cohort studies (52,55,56), NLR was reported to be a risk factor for PD. However, in two case-control studies (54,57), the authors reported that NLR was not a risk factor for PD. In another study, the authors reported that NLR was higher in the patients with preterm premature rupture of membranes and it was a predictor of neonatal sepsis (53).


Conclusions

To date, accumulated studies have investigated the clinical utility of NLR in PRCs (Table 1). However, the results were not always consistent. This may be due to the small sample sizes and low statistical power in some studies. Therefore, meta-analysis may be needed to pool the results of available results in future. Notably, majority of evidences is case-control or cross-sectional design and multivariable analysis is not performed in large portion of available studies. Therefore, prospective cohort studies with large sample sizes and fully-adjusted analyses are needed to rigorously evaluate the clinical utility of NLR in PRCs.

Table 1
Table 1 Current evidence on neutrophil to lymphocyte ratio and pregnancy-related complications.
Full table

Acknowledgments

None.


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.


References

  1. Benites-Zapata VA, Hernandez AV, Nagarajan V, et al. Usefulness of Neutrophil-to-Lymphocyte Ratio in Risk Stratification of Patients With Advanced Heart Failure. Am J Cardiol 2015;115:57-61. [Crossref] [PubMed]
  2. Huang YL, Han ZJ, Hu ZD. Red blood cell distribution width and neutrophil to lymphocyte ratio are associated with outcomes of adult subarachnoid haemorrhage patients admitted to intensive care unit. Ann Clin Biochem 2017;54:696-701. [PubMed]
  3. Hu ZD, Huang YL, Qin BD, et al. Prognostic value of neutrophil to lymphocyte ratio for gastric cancer. Ann Transl Med 2015;3:50. [PubMed]
  4. Bhat T, Teli S, Rijal J, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther 2013;11:55-9. [Crossref] [PubMed]
  5. Galliazzo S, Nigro O, Bertù L, et al. Prognostic role of neutrophils to lymphocytes ratio in patients with acute pulmonary embolism: a systematic review and meta-analysis of the literature. Intern Emerg Med 2018;13:603-8. [Crossref] [PubMed]
  6. Harmon AC, Cornelius DC, Amaral LM, et al. The role of inflammation in the pathology of preeclampsia. Clin Sci 2016;130:409-19. [Crossref] [PubMed]
  7. Vrachnis N, Vitoratos N, Iliodromiti Z, et al. Intrauterine inflammation and preterm delivery. Ann N Y Acad Sci 2010;1205:118-22. [Crossref] [PubMed]
  8. Perucci LO, Corrêa MD, Dusse LM, et al. Resolution of inflammation pathways in preeclampsia—a narrative review. Immunol Res 2017;65:774-89. [Crossref] [PubMed]
  9. Kara AE, Guney G, Tokmak A, et al. The role of inflammatory markers hs-CRP, sialic acid, and IL-6 in the pathogenesis of preeclampsia and intrauterine growth restriction. Eur Cytokine Netw 2019;30:29-33. [PubMed]
  10. Raio L, Bersinger NA, Malek A, et al. Ultra-high sensitive C-reactive protein during normal pregnancy and in preeclampsia. J Hypertens 2019;37:1012-7. [Crossref] [PubMed]
  11. Haedersdal S, Salvig JD, Aabye M, et al. Inflammatory Markers in the Second Trimester Prior to Clinical Onset of Preeclampsia, Intrauterine Growth Restriction, and Spontaneous Preterm Birth. Inflammation 2013;36:907-13. [Crossref] [PubMed]
  12. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365:785-99. [Crossref] [PubMed]
  13. Xiao J, Shen F, Xue Q, et al. Is ethnicity a risk factor for developing preeclampsia? An analysis of the prevalence of preeclampsia in China. J Hum Hypertens 2014;28:694-8. [Crossref] [PubMed]
  14. Rezende KB, Bornia RG, Esteves AP, et al. Preeclampsia: Prevalence and perinatal repercussions in a University Hospital in Rio de Janeiro, Brazil. Pregnancy Hypertens 2016;6:253-5. [Crossref] [PubMed]
  15. Khader YS, Batieha A, Al-njadat RA, et al. Preeclampsia in Jordan: incidence, risk factors, and its associated maternal and neonatal outcomes. J Matern Fetal Neonatal Med 2018;31:770-6. [Crossref] [PubMed]
  16. Aggarwal R, Jain AK, Mittal P, et al. Association of pro- and anti-inflammatory cytokines in preeclampsia. J Clin Lab Anal 2019;33:e22834. [Crossref] [PubMed]
  17. Wu LZ, Xiao XM. Evaluation of the effects of Uncaria rhynchophylla alkaloid extract on LPS-induced preeclampsia symptoms and inflammation in a pregnant rat model. Braz J Med Biol Res 2019;52:e8273. [Crossref] [PubMed]
  18. Yavuzcan A, Cağlar M, Ustün Y, et al. Mean platelet volume, neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in severe preeclampsia. Ginekol Pol 2014;85:197-203. [Crossref] [PubMed]
  19. Oylumlu M, Ozler A, Yildiz A, et al. New inflammatory markers in pre-eclampsia: echocardiographic epicardial fat thickness and neutrophil to lymphocyte ratio. Clin Exp Hypertens 2014;36:503-7. [Crossref] [PubMed]
  20. Mannaerts D, Heyvaert S, De Cordt C, et al. Are neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and/or mean platelet volume (MPV) clinically useful as predictive parameters for preeclampsia? J Matern Fetal Neonatal Med 2019;32:1412-9. [Crossref] [PubMed]
  21. Wang J, Zhu QW, Cheng XY, et al. Assessment efficacy of neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in preeclampsia. J Reprod Immunol 2019;132:29-34. [Crossref] [PubMed]
  22. Sitotaw C, Asrie F, Melku M. Evaluation of platelet and white cell parameters among pregnant women with Preeclampsia in Gondar, Northwest Ethiopia: A comparative cross-sectional study. Pregnancy Hypertens 2018;13:242-7. [Crossref] [PubMed]
  23. Cakmak HA, Dincgez Cakmak B, Abide Yayla C, et al. Assessment of relationships between novel inflammatory markers and presence and severity of preeclampsia: Epicardial fat thickness, pentraxin-3, and neutrophil-to-lymphocyte ratio. Hypertens Pregnancy 2017;36:233-9. [Crossref] [PubMed]
  24. Serin S, Avcı F, Ercan O, et al. Is neutrophil/lymphocyte ratio a useful marker to predict the severity of pre-eclampsia? Pregnancy Hypertens 2016;6:22-5. [Crossref] [PubMed]
  25. Kurtoglu E, Kokcu A, Celik H, et al. May ratio of neutrophil to lymphocyte be useful in predicting the risk of developing preeclampsia? A pilot study. J Matern Fetal Neonatal Med 2015;28:97-9. [Crossref] [PubMed]
  26. Gogoi P, Sinha P, Gupta B, et al. Neutrophil-to-lymphocyte ratio and platelet indices in pre-eclampsia. Int J Gynaecol Obstet 2019;144:16-20. [Crossref] [PubMed]
  27. Yücel B, Ustun B. Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume, red cell distribution width and plateletcrit in preeclampsia. Pregnancy Hypertens 2017;7:29-32. [Crossref] [PubMed]
  28. Jeon Y, Lee WI, Kang SY, et al. Modified Complete Blood Count Indices as Predicting Markers of Preeclampsia from Gestational Hypertension: Neutrophil to Lymphocyte Ratio, Platelet to Lymphocyte Ratio, and. Clin Lab 2017;63:1897-902. [Crossref] [PubMed]
  29. Örgül G, Aydın Haklı D, Özten G, et al. First trimester complete blood cell indices in early and late onset preeclampsia. Turk J Obstet Gynecol 2019;16:112-7. [Crossref] [PubMed]
  30. Gezer C, Ekin A, Ertas IE, et al. High first-trimester neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios are indicators for early diagnosis of preeclampsia. Ginekol Pol 2016;87:431-5. [Crossref] [PubMed]
  31. Panwar M, Kumari A, Hp A, et al. Raised neutrophil lymphocyte ratio and serum beta hCG level in early second trimester of pregnancy as predictors for development and severity of preeclampsia. Drug Discov Ther 2019;13:34-7. [Crossref] [PubMed]
  32. Dusse LM, Alpoim PN, Silva JT, et al. Revisiting HELLP syndrome. Clin Chim Acta 2015;451:117-20. [Crossref] [PubMed]
  33. Aloizos S, Seretis C, Liakos N, et al. HELLP syndrome: Understanding and management of a pregnancy-specific disease. J Obstet Gynaecol 2013;33:331-7. [Crossref] [PubMed]
  34. Sisti G, Faraci A, Silva J, et al. Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Routine Complete Blood Count Components in HELLP Syndrome: A Matched Case Control Study. Medicina (Kaunas) 2019;55:123. [Crossref] [PubMed]
  35. Sisti G, Faraci A, Silva J, et al. Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio and Complete Blood Count Components in the First Trimester Do Not Predict HELLP Syndrome. Medicina (Kaunas) 2019;55:219. [Crossref] [PubMed]
  36. Lekva T, Norwitz ER, Aukrust P, et al. Impact of Systemic Inflammation on the Progression of Gestational Diabetes Mellitus. Curr Diab Rep 2016;16:26. [Crossref] [PubMed]
  37. Yilmaz H, Celik HT, Namuslu M, et al. Benefits of the neutrophil-to-lymphocyte ratio for the prediction of gestational diabetes mellitus in pregnant women. Exp Clin Endocrinol Diabetes 2014;122:39-43. [Crossref] [PubMed]
  38. Sargın MA, Yassa M, Taymur BD, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: are they useful for predicting gestational diabetes mellitus during pregnancy? Ther Clin Risk Manag 2016;12:657-65. [Crossref] [PubMed]
  39. Basu J, Datta C, Chowdhury S, et al. Gestational Diabetes Mellitus in a Tertiary Care Hospital of Kolkata, India: Prevalence, Pathogenesis and Potential Disease Biomarkers. Exp Clin Endocrinol Diabetes 2018. [Epub ahead of print].
  40. Shaw JL, Diamandis EP, Horne AW, et al. Ectopic pregnancy. Clin Chem 2012;58:1278-85. [Crossref] [PubMed]
  41. Akkaya H, Uysal G. Can hematologic parameters predict treatment of ectopic pregnancy? Pak J Med Sci 2017;33:937-42. [Crossref] [PubMed]
  42. Kanmaz AG, İnan AH, Beyan E, et al. Role of various complete blood count parameters in predicting the success of single-dose Methotrexate in treating ectopic pregnancy. Pak J Med Sci 2018;34:1132-6. [Crossref] [PubMed]
  43. Kan Ö, Gemici A, Alkilic A, et al. The Effect of Preoperative Neutrophil-To-Lymphocyte Ratio and Platelet-To-Lymphocyte Ratio on Predicting Rupture Risk in Tubal Ectopic Pregnancies. Gynecol Obstet Invest 2019;84:378-82. [Crossref] [PubMed]
  44. Cekmez Y, Göçmen A, Sanlιkan F, et al. Role of mean platelet volume and neutrophil/lymphocyte ratio to predict single-dose methotrexate treatment success in tubal ectopic pregnancy. Clin Exp Obstet Gynecol 2016;43:509-11. [PubMed]
  45. Austin K, Wilson K, Saha S. Hyperemesis Gravidarum. Nutr Clin Pract 2019;34:226-41. [Crossref] [PubMed]
  46. Caglayan EK, Engin-Ustun Y, Gocmen AY, et al. Is there any relationship between serum sirtuin-1 level and neutrophil-lymphocyte ratio in hyperemesis gravidarum? J Perinat Med 2016;44:315-20. [Crossref] [PubMed]
  47. Kurt RK, Güler A, Silfeler DB, et al. Relation of inflammatory markers with both presence and severity of hyperemesis gravidarum. Ginekol Pol 2014;85:589-93. [Crossref] [PubMed]
  48. Tayfur C, Burcu DC, Gulten O, et al. Association between platelet to lymphocyte ratio, plateletcrit and the presence and severity of hyperemesis gravidarum. J Obstet Gynaecol Res 2017;43:498-504. [Crossref] [PubMed]
  49. Çintesun E, Akar S, Gul A, et al. Subclinical inflammation markers in hyperemesis gravidarum and ketonuria: A case-control study. J Lab Physicians 2019;11:149. [Crossref] [PubMed]
  50. Beyazit F, Öztürk FH, Pek E, et al. Evaluation of the hematologic system as a marker of subclinical inflammation in hyperemesis gravidarum: a case control study. Ginekol Pol 2017;88:315-9. [Crossref] [PubMed]
  51. Kan E, Emektar E, Corbacioglu K, et al. Evaluation of relationship between inflammatory markers and hyperemesis gravidarum in patients admitted to emergency department. Am J Emerg Med 2019. [Epub ahead of print]. [Crossref] [PubMed]
  52. Kim MA, Lee BS, Park YW, et al. Serum markers for prediction of spontaneous preterm delivery in preterm labour. Eur J Clin Invest 2011;41:773-80. [Crossref] [PubMed]
  53. Ozel A, Alici Davutoglu E, Yurtkal A, et al. How do platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio change in women with preterm premature rupture of membranes, and threaten preterm labour? J Obstet Gynaecol 2019.1-5. [Epub ahead of print]. [Crossref] [PubMed]
  54. Daglar HK, Kirbas A, Kaya B, et al. The value of complete blood count parameters in predicting preterm delivery. Eur Rev Med Pharmacol Sci 2016;20:801-5. [PubMed]
  55. Bozoklu Akkar O, Sancakdar E, Karakus S, et al. Evaluation of Maternal Serum 25-Hydroxyvitamin D, Paraoxonase 1 Levels, and Neutrophil-to-Lymphocyte Ratio in Spontaneous Preterm Birth. Med Sci Monit 2016;22:1238-43. [Crossref] [PubMed]
  56. Gezer C, Ekin A, Solmaz U, et al. Identification of preterm birth in women with threatened preterm labour between 34 and 37 weeks of gestation. J Obstet Gynaecol 2018;38:652-7. [Crossref] [PubMed]
  57. Isık H, Aynıoglu O, Sahbaz A, et al. Can plateletcrit, an underestimated platelet parameter, be related with preterm labour? J Obstet Gynaecol 2015;35:676-80. [Crossref] [PubMed]
doi: 10.21037/jlpm.2019.10.03
Cite this article as: Hai L, Hu ZD. The clinical utility of neutrophil to lymphocyte ratio in pregnancy related complications: a mini-review. J Lab Precis Med 2020;5:1.